Abstract
The transcription factor E2F1 is a key component of cell cycle that acts to transactivate genes required for S phase entry. Thus, it plays an important role in cellular proliferation, oncogenesis and differentiation. In order to investigate its potential implication in human lung carcinogenesis, we studied E2F1 protein expression by Western blotting and immunohistochemistry in a series of 58 human lung tumours of all histological types. We showed that E2F1 product was overexpressed in 92% (24/26) of small cell lung carcinoma (SCLC) and in 50% (5/10) of large cell neuroendocrine carcinoma (LCNEC) whereas it was undetectable in 90% (10/11) of adenocarcinoma and 82% (9/11) of squamous carcinoma when compared to corresponding normal lung. No amplification was found but an increase in E2F1 mRNA expression was detected in 75% (18/24) of SCLC overexpressing E2F1 product. In these tumours and in contrast with NSCLC, upregulation of E2F1 product was associated with its nuclear accumulation and with overexpression of several of its target-genes. Moreover, E2F1 overexpression in NE lung tumours was significantly associated with a high KI67 index (P<0.0001) as well as a Bcl-2:Bax ratio >1 (P<0.001). Overall, these results demonstrate a distinct pattern of E2F1 expression in human lung tumours and suggest that its deregulation could be involved in the carcinogenesis of SCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allen KE, de la Luna S, Kerkhoven RM, Bernards R, La Thangue NB . 1997 J. Cell Sci. 110: 2819–2831
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH . 1998 Nature 395: 124–125
Brambilla E, Gazzeri S, Moro D, Caron de Fromentel C, Gouyer V, Jacrot M, Brambilla C . 1993 Am. J. Pathol. 143: 199–210
Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, Coll JL . 1996 Am. J. Pathol. 149: 1941–1952
Brambilla E, Moro D, Gazzeri S, Brambilla C . 1997 J. Path. 188: 351–360
Campanero MR, Flemington EK . 1997 Proc. Natl. Acad. Sci. USA 94: 2221–2226
Chiba I, Takahashi T, Nau M . 1990 Oncogene 5: 1603–1610
Chomczynski PT, Sacchi N . 1987 Ann. Biochem. 162: 156–159
De La Luna S, Burden MJ, Lee CW, La Thangue NB . 1996 J. Cell Sci. 109: 2443–2452
DeGregori J, Kowalik T, Nevins JR . 1995 Mol. Cell. Biol. 15: 4215–4224
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR . 1997 Proc. Natl. Acad. Sci. USA 94: 7245–7250
DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA, Willey JC . 1998 Am. J. Respir. Cell. Mol. Biol. 19: 18–24
Dyson N . 1998 Genes Dev. 12: 2245–2262
Field SJ, Tsai FY, Kuo F, Zubagia AM, Kaelin WG, Livingston DM, Orkin SH, Greenberg ME . 1996 Cell 85: 549–561
Flemington EK, Speck SH, Kaelin WG . 1993 Proc. Natl. Acad. Sci. USA 90: 6914–6918
Gazzeri S, Brambilla E, Caron de Fromentel C, Gouyer V, Moro D, Perron P, Berger F, Brambilla C . 1994 Int. J. Cancer 58: 24–32
Gazzeri S, Gouyer V, Vourc'h C, Brambilla C, Brambilla E . 1998a Oncogene 16: 497–505
Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E . 1998b Cancer Res. 58: 3926–3931
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H . 1984 J. Immunol. 133: 1710–1715
Gouyer V, Gazzeri S, Bolon I, Drevet C, Brambilla C, Brambilla E . 1998 Am. J. Respir. Cell Mol. Biol. 17: 1–9
Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL . 1996 Genes Dev. 10: 2960–2970
Helin K . 1998 Curr. Opin. Genet. Dev. 8: 28–35
Hofmann F, Martelli F, Livingston DM, Wang ZY . 1996 Genes Dev. 10: 2949–2959
Johnson DG, Schwarz JK, Cress WD, Nevins JR . 1993 Nature 365: 349–352
Johnson DG, Ohtani K, Nevins JR . 1994 Genes Dev. 8: 1514–1525
Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE . 1997 J. Nat. Cancer. Inst. 87: 756–761
Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR . 1998 Cell Growth Differ. 9: 113–118
Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR . 1997 Nature 387: 422–426
Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D . 1997 Proc. Natl. Acad. Sci. USA. 94: 5095–5100
Marti A, Wirbelauer C, Scheffner M, Krek W . 1999 Nature Cell Biol. 1: 14–19
Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T . 1995 Nature 375: 691–694
Mittnacht S . 1998 Curr. Opin. Genet. Dev. 8: 21–27
Neuman E, Flemington EK, Sellers WR, Kaelin WG . 1994 Mol. Cell. Biol. 14: 6607–6615
Nevins JR . 1992 Science 258: 424–429
O'Connor DJ, Lam EWF, Griffin S, Zhong S, Leighton LC, Burbidge SA, Lu X . 1995 EMBO J. 14: 6184–6192
Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH . 1999 Mol. Cell. 4: 771–781
Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG . 1998 Proc. Natl. Acad. Sci. USA 95: 8858–8863
Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG . 1999 Mol. Cell. Biol. 19: 6408–6414
Qin XQ, Livingston DM, Kaelin WG, Adams P . 1994 Proc. Natl. Acad. Sci. USA 91: 10918–10922
Shan B, Lee WH . 1994 Mol. Cell. Biol. 14: 8166–8173
Shan B, Durfee T, Lee WH . 1996 Proc. Natl. Acad. Sci. USA 93: 679–684
Sherr CJ . 1996 Science 274: 1672–1677
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E . 1999 WHO International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours. Third Edition. Ed Springer
Vandel L, Kouzarides T . 1999 EMBO J. 18: 4280–4291
Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, Helin K . 1999 Mol. Cell. Biol. 19: 6379–6395
Volm M, Koomagi R, Rittgen W . 1998 Int. J. Cancer 79: 294–299
Wade Harper J, Elledge SJ . 1999 Nature Cell Biol. 1: E5–E7
Weintraub SJ, Chow K, Luo RX, Zhang SH, He S, Dean DC . 1995 Nature 375: 812–815
Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA . 1995 Mol. Cell. Biol. 15: 2536–2546
Wu X, Levine AJ . 1994 Proc. Natl. Acad. Sci. USA 91: 3601–3606
Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF . 1996 Clin. Cancer Res. 2: 1169–1176
Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ . 1996 Cell 85: 537–548
Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM . 2000 Clin. Cancer Res. 6: 1579–1589
Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudowi T, Takahashi T . 1998 Cancer Res. 58: 1042–1047
Zhang HS, Postigo AA, Dean DC . 1999 Cell 97: 53–61
Acknowledgements
This work was supported by grants from the Association pour la Recherche sur le Cancer, from the Comité Départemental de la Ligue contre le Cancer de l'Isère and from the Groupement des Entreprises Francaises dans la Lutte contre le Cancer. B Eymin was supported by INSERM (Poste Accueil).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eymin, B., Gazzeri, S., Brambilla, C. et al. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 20, 1678–1687 (2001). https://doi.org/10.1038/sj.onc.1204242
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204242
Keywords
This article is cited by
-
Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells
World Journal of Surgical Oncology (2022)
-
Asxl1 exerts an antiproliferative effect on mouse lung maturation via epigenetic repression of the E2f1-Nmyc axis
Cell Death & Disease (2018)
-
Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype
BMC Cancer (2014)
-
KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress
Cell Death & Differentiation (2014)
-
Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
Cell Death & Disease (2014)